Scholar Rock Reports Q1 2026 Earnings with Positive FDA Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy SRRK?
Source: seekingalpha
- FDA Application Progress: Scholar Rock's biologics license application (BLA) has been accepted for review by the FDA, with a decision expected by September 30, establishing a solid foundation for market entry in the treatment of spinal muscular atrophy (SMA).
- Production Capacity Assurance: The BLA includes two fill-finish facilities located in Indiana and a second U.S. facility, ensuring that Scholar Rock can rapidly meet market demand upon approval, thereby enhancing its commercial supply capabilities.
- Strong Financial Position: The company ended the first quarter with $480 million in cash and cash equivalents, and secured an additional $100 million from its existing debt facility, demonstrating robust financial support to address the upcoming product launch.
- European Market Outlook: Management indicated that the EMA review of apitegromab is progressing well, with a CHMP opinion anticipated mid-year, which will provide favorable conditions for the company's expansion into the European market, further strengthening its global competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 46.450
Low
42.00
Averages
50.00
High
60.00
Current: 46.450
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock Reports Q1 2026 Earnings with Positive FDA Progress
- FDA Application Progress: Scholar Rock's biologics license application (BLA) has been accepted for review by the FDA, with a decision expected by September 30, establishing a solid foundation for market entry in the treatment of spinal muscular atrophy (SMA).
- Production Capacity Assurance: The BLA includes two fill-finish facilities located in Indiana and a second U.S. facility, ensuring that Scholar Rock can rapidly meet market demand upon approval, thereby enhancing its commercial supply capabilities.
- Strong Financial Position: The company ended the first quarter with $480 million in cash and cash equivalents, and secured an additional $100 million from its existing debt facility, demonstrating robust financial support to address the upcoming product launch.
- European Market Outlook: Management indicated that the EMA review of apitegromab is progressing well, with a CHMP opinion anticipated mid-year, which will provide favorable conditions for the company's expansion into the European market, further strengthening its global competitiveness.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
Scholar Rock Reports Q1 2026 Earnings with Positive FDA Progress
- FDA Application Progress: Scholar Rock's biologics license application (BLA) has been accepted for review by the FDA, with a decision expected by September 30, establishing a solid foundation for market entry in the treatment of spinal muscular atrophy (SMA).
- Production Capacity Assurance: The BLA includes two fill-finish facilities located in Indiana and a second U.S. facility, ensuring that Scholar Rock can rapidly meet market demand upon approval, thereby enhancing its commercial supply capabilities.
- Strong Financial Position: The company ended the first quarter with $480 million in cash and cash equivalents, and secured an additional $100 million from its existing debt facility, demonstrating robust financial support to address the upcoming product launch.
- European Market Outlook: Management indicated that the EMA review of apitegromab is progressing well, with a CHMP opinion anticipated mid-year, which will provide favorable conditions for the company's expansion into the European market, further strengthening its global competitiveness.
See More
Key Wall Street Rating Changes Overview
- LCI Industries Upgrade: Roth upgrades LCI Industries from Hold to Buy with a price target of $164, unchanged, following outsized Q1 EPS, indicating strong profitability that is expected to drive stock price upward.
- VF Corp Upgrade: BTIG raises VF Corp's rating from Neutral to Buy, citing more reasonable estimates reflecting positive outlook for Vans brand, which could enhance market confidence and shareholder returns.
- DaVita's Strong Performance: Deutsche Bank upgrades DaVita from Hold to Buy after reporting Q1 revenues of $3.415 billion, beating consensus by 2.2%, and EPS of $2.87, exceeding expectations by 22.1%, showcasing robust treatment growth and revenue per treatment.
- Monster Beverage Upgrade: Rothschild & Co Redburn upgrades Monster Beverage from Neutral to Buy, highlighting significant international growth potential as the company currently holds only 14% market share, suggesting substantial future market position improvement.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
US Stocks Surge on Hopes for End to Iran War
- Market Rally: The S&P 500 index rose by 2.91%, the Dow Jones Industrial Average by 2.49%, and the Nasdaq 100 by 3.43%, reflecting market optimism regarding the potential end of the Iran war, which could lower energy prices and ease inflation concerns.
- Consumer Confidence Boost: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing the anticipated decline to 87.9, indicating a strengthening consumer outlook that may drive spending and economic growth.
- Strength in China: China's March manufacturing PMI rose to 50.4, better than the expected 50.1, signaling signs of economic recovery that could positively impact global growth prospects and further support US stock performance.
- Falling Bond Yields: The 10-year Treasury note yield dropped to 4.28%, a one-week low, reflecting reduced inflation worries, which may provide support for the stock market and enhance investor interest in equities.
See More
Scholar Rock Resubmits Biologics License Application for SMA Treatment
- Price Target Increase: Raymond James raised Scholar Rock's price target from $53 to $60 while maintaining a ‘Strong Buy’ rating, indicating analysts' confidence in the company's future performance, with expectations of strong market uptake for Apitegromab if approved.
- Regulatory Risk Mitigation: H.C. Wainwright views the resubmission as a ‘material de-risking event’, significantly improving approval chances due to FDA support for manufacturing and increased redundancy, which is expected to accelerate the commercialization process.
- FDA Decision Timeline: The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026, providing the company with a clear timeline to prepare for market launch.
- Positive Retail Investor Sentiment: Retail sentiment on Stocktwits shifted from ‘neutral’ to ‘bullish’, indicating strong market interest in Scholar Rock, with the stock gaining approximately 10% year-to-date, reflecting investor confidence in its future potential.
See More
US Stocks Surge as Market Sentiment Improves
- Market Sentiment Improves: The S&P 500 index rose by 1.02%, the Dow Jones Industrial Average increased by 0.67%, and the Nasdaq 100 surged by 1.10% as President Trump signaled a willingness to end military actions against Iran, reflecting investor optimism over easing geopolitical risks.
- Falling Bond Yields: The 10-year Treasury note yield dropped to a one-week low of 4.30%, indicating market expectations that an end to the Iran conflict could lower energy prices and alleviate inflation concerns, further supporting stock market gains.
- Consumer Confidence Rises: The US March consumer confidence index unexpectedly increased by 0.8 to 91.8, surpassing expectations of a decline to 87.9, suggesting enhanced consumer confidence in economic prospects, which could drive spending and economic growth.
- Strong Chinese Economy: China's March manufacturing PMI rose to 50.4, exceeding expectations of 50.1, indicating signs of economic recovery that support global growth prospects and positively influence market performance.
See More
